Healthcare

Ping An Healthcare runs a digital healthcare platform in China, linking online consultations, health management, and medical product services. Profitability has improved sharply, the balance sheet is strong, and deeper ties with insurers and enterprise clients are reshaping the business.

Omnicell builds medication automation and pharmacy workflow technology for hospitals and pharmacies. The long-term appeal comes from healthcare’s push for safer, more efficient operations, while recent results show improving growth, lower leverage, and a steadier cash profile.

Omeros is a biotech centered on complement-based drug development, with narsoplimab as the key value driver. Recent operating improvement and renewed market interest have sharpened attention on its pipeline, regulatory progress, and strategic flexibility.

Ocular Therapeutix is building an eye-disease platform centered on sustained drug delivery, with its biggest opportunity in retinal treatments. The current business is small, but successful late-stage progress could meaningfully expand its role in a large and growing market.

Phibro Animal Health sells livestock health and nutrition products, with animal health driving most revenue. Recent years brought stronger sales, margins, and earnings, making the company a more profitable niche player in a durable food-production market.

Össur makes prosthetic limbs, braces, and orthopedic support products for mobility care. Recent results show steady revenue growth, strong margins, and rising cash generation, giving the company a stronger long-term profile than its muted stock performance suggests.